Elucidating the cytogenotoxic potential of gabapentin: in vitro and in silico analysis

Yıl 2025, Cilt: 50 Sayı: 2, 435 - 442, 30.06.2025

İbrahim Halil Kenger , Mehmet Tahir Hüsunet

https://doi.org/10.17826/cumj.1629309

https://izlik.org/JA56CJ89ZJ

Öz

Purpose: This investigation aimed to evaluate the potential cytogenotoxic effects of gabapentin (GBP) on neuroblastoma cells (SH-SY5Y cell line) given its broad range of applications. Furthermore, the interaction between GBP and DNA polymerase beta (DNApolβ) was evaluated using in silico methods.
Material and Methods: The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was used to investigate the cytotoxicity of GBP at concentrations of 1 µM, 10 µM, 100 µM and 1000 µM. The IC₅₀ value of GBP was calculated, as were the genotoxic effects of GBP at concentrations of 0.14 µM, 0.28 µM, 0.56 µM and 1.12 µM, using the Comet assay. Additionally, AutoDock 4.0 was used to predict the interaction between GBP and the DNApolβ molecule in silico.
Results: GBP significantly decreased the viability of SH-SY5Y cells by 70.2 ± 3.084% and 86.8 ± 3.324% at concentrations of 1 µM and 10 µM, respectively. Concentrations of GBP (0.14 µM, 0.28 µM, 0.56 µM and 1.12 µM) were found to be statistically significant for the damaged cell index (DCI) in SH-SY5Y cells at 298.219 ± 104.66, 593.436 ± 120.16, 1216.378 ± 215.96 and 1589.733 ± 472.65, respectively. The genetic damage index (GDI) for these concentrations was found to be statistically significant at 4.150 ± 1.92, 6.568 ± 1.27, 8.216 ± 0.60 and 9.181 ± 1.16, respectively. The Gibbs free binding energy of GBP with DNApolβ was calculated as -7.35 kcal/mol.
Conclusion: The results of this study indicate that GBP, used in the treatment of epilepsy and neuropathic pain, increases both cytotoxicity and genotoxicity in SH-SY5Y neuroblastoma cells. Furthermore, in silico predictions have revealed a significant interaction between GBP and DNApolβ.

Anahtar Kelimeler

Neuroblastoma , Gabapentin , genotoxicity , cytotoxicity , SH-SY5Y cell line , in slico molecular docking

Etik Beyan

No ethics committee authorisation required

Gabapentinin sitogenotoksik potansiyelinin aydınlatılması: in vitro ve siliko analizi

https://izlik.org/JA56CJ89ZJ

Öz

Amaç: Bu araştırma, geniş uygulama alanı göz önüne alındığında, gabapentinin (GBP) nöroblastoma hücreleri (SH-SY5Y hücre hattı) üzerindeki potansiyel sitogenotoksik etkilerini değerlendirmeyi amaçlamıştır. Ayrıca, GBP ve DNA polimeraz beta (DNApolβ) arasındaki etkileşim in silico yöntemler kullanılarak değerlendirilmiştir.
Gereç ve Yöntem: 3-(4,5-dimetiltiyazol-2-il)-5-(3-karboksimetoksifenil)-2-(4-sülfofenil)-2H-tetrazolyum (MTS) deneyi, 1 µM, 10 µM, 100 µM ve 1000 µM konsantrasyonlarında GBP'nin sitotoksisitesini araştırmak için kullanılmıştır. Comet deneyi kullanılarak GBP'nin IC₅₀ değeri ve 0,14 µM, 0,28 µM, 0,56 µM ve 1,12 µM konsantrasyonlarında GBP'nin genotoksik etkileri hesaplanmıştır. Ek olarak, GBP ve DNApolβ molekülü arasındaki etkileşimi in silico tahmin etmek için AutoDock 4.0 kullanılmıştır.
Bulgular: GBP, SH-SY5Y hücrelerinin canlılığını 1 µM ve 10 µM konsantrasyonlarında sırasıyla %70,2 ± 3,084 ve %86,8 ± 3,324 oranında önemli ölçüde azaltmıştır. GBP konsantrasyonları (0.14 µM, 0.28 µM, 0.56 µM ve 1.12 µM) SH-SY5Y hücrelerinde hasarlı hücre indeksi (DCI) için sırasıyla 298.219 ± 104.66, 593.436 ± 120.16, 1216.378 ± 215.96 ve 1589.733 ± 472.65 değerlerinde istatistiksel olarak anlamlı bulunmuştur. Bu konsantrasyonlar için genetik hasar indeksi (GDI) sırasıyla 4.150 ± 1.92, 6.568 ± 1.27, 8.216 ± 0.60 ve 9.181 ± 1.16 olarak istatistiksel olarak anlamlı bulunmuştur. GBP'nin DNApolβ ile Gibbs serbest bağlanma enerjisi -7,35 kcal/mol olarak hesaplanmıştır.
Sonuç: Bu çalışmanın sonuçları, epilepsi ve nöropatik ağrı tedavisinde kullanılan GBP'nin SH-SY5Y nöroblastoma hücrelerinde hem sitotoksisiteyi hem de genotoksisiteyi artırdığını göstermektedir. Dahası, in silico tahminler GBP'nin DNApolβ ile önemli bir etkileşim içinde olduğunu göstermiştir.

Anahtar Kelimeler

nöroblastoma , gabapentin , genotoksisite , sitotoksisite , SH-SY5Y hücre hattı , in slico moleküler yerleştirme

Etik Beyan

Etik kurul izni gerekli değildir.

Kaynakça

• Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149:778-89.
• Nijs J, Lahousse A, Fernández-de-Las-Peñas C, Madeleine P, Fontaine C, Nishigami T et al. Towards precision pain medicine for pain after cancer: the cancer pain phenotyping network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria. Br J Anaesth. 2023;130:611-21.
• Mulvey MR, Paley CA, Schuberth A, King N, Page A, Neoh K. Neuropathic pain in cancer: what are the current guidelines? Curr Treat Options Oncol. 2024;25:1193-202.
• Taverner T. Neuropathic pain in people with cancer (part 2): pharmacological and non-pharmacological management. Int J Palliat Nurs. 2015;21:380-4.
• Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2020;101:259-301.
• Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-6.
• Bosnjak S, Jelic S, Susnjar S, Lukic V. Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. J Chemother. 2002;14:214-9.
• Schlereth T. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German society of neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract. 2020;2:16.
• Happe S, Sauter C, Klösch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003;48:82-6.
• Carta MG, Hardoy MC, Hardoy MJ, Grunze H, Carpiniello B. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord. 2003;75:83-91.
• Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119-28.
• Bao H, Wu Z, Wang Q, Wang J, Zhang L, Meng L et al. The efficacy of gabapentin combined with opioids for neuropathic cancer pain: a meta-analysis. Transl Cancer Res. 2021;10:637.
• Baldewig M, Goldbaum O, Richter-Landsberg C, Weyland A, Bantel C. Short-term incubation of gabapentin or pregabalin does not affect chemically induced injury in neuronal cell models in vitro. J Pain Res. 2018:1181-90.
• Prakash PL, Rai R, Pai M, Yadav S, Madhyastha S, Goel R et al. Teratogenic effects of the anticonvulsant gabapentin in mice. Singapore Med J. 2008;49:47-53.
• Al‐Musawi M, Durham J, Whitworth JM, Stone SJ, Nixdorf DR, Valentine RA. Effect of topical neuromodulatory medications on oral and skin keratinocytes. J Oral Pathol Med. 2017;46:134-41.
• Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78-94.
• Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184-91.
• 18.Tabakcioglu K. et al. Investigation of the radioprotective effect of myricetin on the DNA of the human lymphocytes. Toxicol Lett. 2016;258:137–38.
• Ricci CG, Netz PA. Docking studies on DNA-ligand interactions: building and application of a protocol to identify the binding mode. J Chem Inf Model. 2009;49:1925-35.
• Nasab RR, Hassanzadeh F, Khodarahmi GA, Rostami M, Mirzaei M, Jahanian-Najafabadi A et al. Docking study, synthesis and antimicrobial evaluation of some novel 4-anilinoquinazoline derivatives. Res Pharm Sci. 2017;12:425-33.
• Husunet MT, Mısırlı RÇ, Istıflı ES, Ila HB. Investigation of the genotoxic effects of patent blue V (E131) in human peripheral lymphocytes and in silico molecular docking. Drug Chem Toxicol. 2022;45:1780-6.
• Botts SR, Raskind J. Gabapentin and lamotrigine in bipolar disorder. Am J Health Syst Pharm. 1999;56:1939-44.
• Montouris G. Gabapentin exposure in human pregnancy: results from the gabapentin pregnancy registry. Epilepsy Behav. 2003;4:310-7.
• Deutsch WA, Kukreja A, Shane B, Hegde V. Phenobarbital, oxazepam and wyeth 14,643 cause DNA damage as measured by the comet assay. Mutagenesis. 2001;16:439-42.
• Lu Y, Liu Y, Yang C. Evaluating in vitro DNA damage using comet assay. J Vis Exp. 2017;128:e56450.
• Magdalou I, Lopez BS, Pasero P, Lambert SA, editors. The causes of replication stress and their consequences on genome stability and cell fate. Semin Cell Dev Biol. 2014;30:154-64.
• Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol.2014;16:2-9.
• Kardoost M, Hajizadeh-Saffar E, Ghorbanian MT, Ghezelayagh Z, Bagheri KP, Behdani M et al. Genotoxicity assessment of antiepileptic drugs (AEDs) in human embryonic stem cells. Epilepsy res. 2019;158:106232.
• Yüksel M, Sarıkaya R, Bostanci N. Genotoxic evaluation of antiepileptic drugs by drosophila somatic mutation and recombination test. Food Chem Toxicol. 2010;48:2682-7.
• Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS med. 2020;17:e1003322.
• Pethusamy K, Kulandhasamy M, Jain A. Encyclopedia of Animal Cognition and Behavior: Teratogen. 1 nd ed (Vonk J and Shackelford TK): 6903-5. Rochester.
• Öztürk Z. İlaç kullanan gebeye yaklaşım: Teratojenite riski ve danışmanlık hizmeti. Sted. 2014;23:1-5.
• Sánchez-Salazar MG, Álvarez MM, Trujillo-de Santiago G. Advances in 3D bioprinting for the biofabrication of tumor models. Bioprinting. 2021;21:e00120.
• Kwak S, Choi YS, Na HG, Bae CH, Song S-Y, Kim Y-D. Glyoxal and methylglyoxal as e-cigarette vapor ingredients-induced pro-inflammatory cytokine and mucins expression in human nasal epithelial cells. Am J Rhinol Allergy. 2021;35:213-20.
• Pearce K, Gray N, Gaur P, Jeon J, Suarez A, Shannahan J et al. Toxicological analysis of aerosols derived from three electronic nicotine delivery systems using normal human bronchial epithelial cells. Toxicol In Vitro. 2020;69:104997.
• Pieters R, Loonen A, Huismans D, Broekema G, Dirven M, Heyenbrok M et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990;76:2327-36.
• Bernas T, Dobrucki J. Mitochondrial and nonmitochondrial reduction of MTT: Interaction of MTT with TMRE, JC‐1, and NAO mitochondrial fluorescent probes. Cytometry. 2002;47:236-42.
• Cardile V, Pavone A, Renis M, Maci T, Perciavalle V. Effects of gabapentin and topiramate in primary rat astrocyte cultures. Neuroreport. 2001;12:1705-8.
• Shityakov S, Förster C. In silico predictive model to determine vector-mediated transport properties for the blood–brain barrier choline transporter. Adv Appl Bioinform Chem. 2014:23-36.
• Kladova OA, Fedorova OS, Kuznetsov NA. The role of natural polymorphic variants of DNA polymerase β in DNA repair. Int J Mol Sci. 2022;23:2390.